BR0207197A - 6,7,8,9-tetraidro-5h-benzocicloeptenil aminas aciladas e seu uso como agente farmacêutico - Google Patents

6,7,8,9-tetraidro-5h-benzocicloeptenil aminas aciladas e seu uso como agente farmacêutico

Info

Publication number
BR0207197A
BR0207197A BR0207197-5A BR0207197A BR0207197A BR 0207197 A BR0207197 A BR 0207197A BR 0207197 A BR0207197 A BR 0207197A BR 0207197 A BR0207197 A BR 0207197A
Authority
BR
Brazil
Prior art keywords
hypertension
benzocycloeptenyl
tetrahydro
amines
diabetes
Prior art date
Application number
BR0207197-5A
Other languages
English (en)
Inventor
Hartmut Strobel
Paulus Wohlfart
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0207197A publication Critical patent/BR0207197A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/74—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

"6,7,8,9-TETRAIDRO-5H-BENZOCICLOEPTENIL AMINAS ACILADAS E SEU USO COMO AGENTE FARMACêUTICO". A presente invenção refere-se a compostos de acordo com a fórmula geral (I) onde R^ 1^-R^ 4^ têm os mesmos significados dados na descrição, A é CH~ 2~, CHOH ou CH(C~ 1~-C~ 3~-alquila), B, C e D são independentemente CH~ 2~ ou CH-(C~ 1~-C~ 3~-alquila), e R^ 5^ é um grupo arila ou heteroarila, possivelmente substituído pelos substituintes listados na descrição. Esses compostos são úteis para a fabricação de medicamentos para o tratamento de doenças cardiovasculares, angina pectoris estável ou instável, doença coronária cardíaca, angina Prinzmetal, síndrome coronária aguda, parada cardíaca, infarto do miocárdio, derrame cerebral, trombose, doença oclusiva arterial periférica, disfunção endotelial, aterosclerose, restenose, dano do endotélio após PTCA, hipertensão, hipertensão essencial, hipertensão pulmonar, hipertensão secundária, hipertensão renovascular, glomerulonefrite crónica, disfunção erétil, arritmia ventricular, diabetes, complicações do diabetes, nefropatia, retinopatia, angiogênese, bronquite asmática, insuficiência renal crónica, cirrose do fígado, osteoporose, ou desempenho da memória restrito ou para uma habilidade restrita em aprender, ou para a diminuição do risco cardiovascular de mulher na pós-menopausa ou após ingestão de anticoncepcionais.
BR0207197-5A 2001-02-13 2002-02-12 6,7,8,9-tetraidro-5h-benzocicloeptenil aminas aciladas e seu uso como agente farmacêutico BR0207197A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01102853 2001-02-13
PCT/EP2002/001449 WO2002064546A2 (en) 2001-02-13 2002-02-12 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical

Publications (1)

Publication Number Publication Date
BR0207197A true BR0207197A (pt) 2004-07-06

Family

ID=8176424

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207197-5A BR0207197A (pt) 2001-02-13 2002-02-12 6,7,8,9-tetraidro-5h-benzocicloeptenil aminas aciladas e seu uso como agente farmacêutico

Country Status (33)

Country Link
US (2) US6759412B2 (pt)
EP (1) EP1362027B1 (pt)
JP (1) JP4319836B2 (pt)
KR (1) KR100975781B1 (pt)
CN (1) CN1296346C (pt)
AR (1) AR035431A1 (pt)
AT (1) ATE396171T1 (pt)
AU (1) AU2002253012B2 (pt)
BG (1) BG108060A (pt)
BR (1) BR0207197A (pt)
CA (1) CA2438324C (pt)
CZ (1) CZ20032134A3 (pt)
DE (1) DE60226704D1 (pt)
DK (1) DK1362027T3 (pt)
EE (1) EE200300370A (pt)
ES (1) ES2304432T3 (pt)
HK (1) HK1061017A1 (pt)
HR (1) HRP20030645A2 (pt)
HU (1) HUP0303133A3 (pt)
IL (2) IL157211A0 (pt)
MX (1) MXPA03006893A (pt)
MY (1) MY136316A (pt)
NO (1) NO328767B1 (pt)
NZ (1) NZ527471A (pt)
PE (1) PE20020870A1 (pt)
PL (1) PL363639A1 (pt)
PT (1) PT1362027E (pt)
RU (1) RU2301797C2 (pt)
SK (1) SK10092003A3 (pt)
UY (1) UY27165A1 (pt)
WO (1) WO2002064546A2 (pt)
YU (1) YU64203A (pt)
ZA (1) ZA200305414B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
AR035431A1 (es) * 2001-02-13 2004-05-26 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
US7176310B1 (en) * 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388342A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7132536B2 (en) * 2003-04-24 2006-11-07 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
AU2004261250B2 (en) 2003-07-29 2009-02-26 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
EP1529525A1 (en) * 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
JP2007277096A (ja) * 2004-07-15 2007-10-25 Astellas Pharma Inc フェネチルニコチンアミド誘導体含有医薬
WO2006053227A2 (en) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
HUE026011T2 (en) 2006-03-22 2016-05-30 Hoffmann La Roche Pyrazoles as 11-beta-HSD-1
EP1905764A1 (en) 2006-09-30 2008-04-02 Sanofi-Aventis Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
DK2588465T3 (en) 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
US20120309796A1 (en) * 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
EP3112363A1 (en) 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
MX361208B (es) 2013-03-15 2018-11-30 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
MX368585B (es) * 2013-06-03 2019-10-08 Sackner Marvin Dispositivo pasivo de trote simulado.
EA032028B1 (ru) 2013-12-11 2019-03-29 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ рГЦ
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CA2959757A1 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
CA2961489A1 (en) 2014-09-17 2016-03-24 Glen Robert RENNIE Sgc stimulators
MA45588A (fr) 2016-07-07 2019-05-15 Ironwood Pharmaceuticals Inc Formes solides d'un stimulateur de la gcs
EP3481837B1 (en) 2016-07-07 2023-12-06 Cyclerion Therapeutics, Inc. Phosphorus prodrugs of sgc stimulators
WO2024091983A1 (en) * 2022-10-25 2024-05-02 Artus Therapeutics, Inc. Therapeutic agents for enhancing epithelial and/or endothelial barrier function

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8402275A (en) * 1974-08-26 1977-02-17 Takeda Chemical Industries Ltd Benzocycloheptene derivatives
DE3807813A1 (de) 1988-03-10 1989-09-21 Thomae Gmbh Dr K Neue benzocycloheptenderivate, diese verbindungen enthaltende arzneimittel und verfahren zu deren herstellung
WO1997006158A1 (en) 1995-08-10 1997-02-20 Astra Aktiebolag Bicyclic amidine derivatives useful in therapy
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
AU4990599A (en) * 1998-07-14 2000-02-07 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AUPP891299A0 (en) 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
AUPQ309399A0 (en) 1999-09-28 1999-10-21 Fujisawa Pharmaceutical Co., Ltd. Benzothiazoline derivatives
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
AR035431A1 (es) * 2001-02-13 2004-05-26 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) * 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

Also Published As

Publication number Publication date
WO2002064546A2 (en) 2002-08-22
IL157211A0 (en) 2004-02-19
WO2002064546A3 (en) 2002-11-07
KR20030077619A (ko) 2003-10-01
EP1362027A2 (en) 2003-11-19
ES2304432T3 (es) 2008-10-16
US6759412B2 (en) 2004-07-06
CA2438324C (en) 2009-07-07
DE60226704D1 (de) 2008-07-03
CN1491208A (zh) 2004-04-21
CA2438324A1 (en) 2002-08-22
RU2003127723A (ru) 2005-03-20
EE200300370A (et) 2003-10-15
UY27165A1 (es) 2002-07-31
CN1296346C (zh) 2007-01-24
HUP0303133A2 (hu) 2003-12-29
PT1362027E (pt) 2008-07-11
RU2301797C2 (ru) 2007-06-27
ZA200305414B (en) 2004-05-20
KR100975781B1 (ko) 2010-08-17
US20040225013A1 (en) 2004-11-11
YU64203A (sh) 2006-05-25
HUP0303133A3 (en) 2007-08-28
IL157211A (en) 2009-05-04
US20030008915A1 (en) 2003-01-09
PL363639A1 (en) 2004-11-29
CZ20032134A3 (cs) 2003-10-15
MY136316A (en) 2008-09-30
ATE396171T1 (de) 2008-06-15
PE20020870A1 (es) 2002-11-18
JP4319836B2 (ja) 2009-08-26
EP1362027B1 (en) 2008-05-21
US7709478B2 (en) 2010-05-04
NO328767B1 (no) 2010-05-10
AR035431A1 (es) 2004-05-26
DK1362027T3 (da) 2008-09-22
NZ527471A (en) 2005-02-25
HRP20030645A2 (en) 2005-06-30
HK1061017A1 (en) 2004-09-03
SK10092003A3 (sk) 2004-01-08
AU2002253012B2 (en) 2008-01-24
JP2004518720A (ja) 2004-06-24
NO20033566L (no) 2003-10-13
NO20033566D0 (no) 2003-08-12
MXPA03006893A (es) 2004-04-02
BG108060A (bg) 2005-01-31

Similar Documents

Publication Publication Date Title
BR0207197A (pt) 6,7,8,9-tetraidro-5h-benzocicloeptenil aminas aciladas e seu uso como agente farmacêutico
BR0207211A (pt) Indanil aminas aciladas e seu uso como produtos farmacêuticos
UY27164A1 (es) 1, 2, 3, 4- tetrahidronaftil aminas aciladas y su uso como farmacos
BR0207178A (pt) 4-flúor-n-indan-2-ii-benzamida e seu uso farmacêutico
BR0313294A (pt) Compostos heteroaromáticos substituìdos com acilamino e seu uso como substâncias farmacêuticas
WO2005082863A3 (en) 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
BR0313240A (pt) Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos
BG106238A (en) Benzothiazinone and benzoxazinone compounds
CA2578596C (en) Substituted phenylaminothiazoles and their use
NO20063928L (no) Substituerte kinolinforbindelser
CL2003002042A1 (es) Compuestos derivados de 3,9-diazabiciclo[3.3.1]noneno; composicion farmaceutica; y uso del compuesto como inhibidor de renina (ras), para tratar hipertension, insuficiencia cardiaca congestiva, hipertension pulmonar, insuficiencia renal, ateroscleros
PT1406898E (pt) Compostos de piperazina substituida e sua utilizacao como inibidores de oxidacao de acidos gordos
BR0311556A (pt) Derivados de n-((3-oxo-2,3-diidro-1h-isoindol-1-il)acetil)guanidina como inibidores de nhe-1 para o tratamento de enfarte e angina pectoris
CA2523196A1 (en) Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
SE0401539D0 (sv) New compounds
MY138896A (en) Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
DE60328545D1 (de) Substituierte Piperazinderivate und ihre Verwendung als Inhibitoren der Fettsäureoxidation
YU81701A (sh) Cinamoilaminoalkil-supstituisani derivati benzensulfonamida
WO2006029179A3 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
PA8552001A1 (es) 1,2,3,4-tetrahidronaftil aminas aciladas y su uso como farmacos
PA8551901A1 (es) Indanil aminas aciladas y su uso como farmacos
PA8552101A1 (es) 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas y su uso como farmacos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07C 233/65; A61P 1/16, 11/06, 13/12, 15/10, 19/10, 25/00, 27/02, 3/10, 35/00, 43/00, 7/02, 9/00, 9/04, 9/06, 9/10, 9/12

Ipc: C07C 233/65 (2011.01), A61P 1/16 (2011.01), A61P 1

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2246 DE 21/01/2014.